Halting Men’s Most Common Cancer
The cancer center is seeking patients with advanced prostate cancer that has spread to the bones to take part in a phase III randomized clinical trial for Alpharadin (pronounced "Alpha-raydin"), an injectable treatment based on the radioactive substance radium-223, an alpha-particle emitting pharmaceutical.
"Alpharadin appears to work by targeting and destroying cancer cells in the bone while sparing healthy bone marrow tissue," said Sartor, Piltz Professor of Cancer Research in the Departments of Medicine and Urology at Tulane. "If successful in clinical trials, this compound could make a significant difference for the large number of men whose cancer has spread to the bones. Patients most often die as a consequence of the metastases — not the primary cancer — so preventing cancer from spreading and controlling cancer that has spread is a major clinical challenge."
All participants will receive the best available standard therapy and are randomized so that two-thirds of the subjects receive Alpharadin in addition. The other third of subjects will receive a placebo along with the standard-of-care therapy.
According to the American Cancer Society, prostate cancer is the most frequently diagnosed cancer in men in the United States. Approximately 27,000 men in the United States die from prostate cancer each year and about 90 percent of these men have bone metastases.
Physicians and patients interested in learning more about this phase III clinical trial can contact the Tulane Cancer Center
at 504-988-7869 or e-mail Sartor
for more information. The trial is being sponsored by Algeta, a Norwegian cancer therapeutics company in partnership with the German pharmaceutical company, Bayer Schering Pharma AG.